Abstract
We asked how psoriasis patients characterized by a hyperadhesive aberrant monocyte (AM endotype) respond to cAMP phosphodiesterase (PDE)-4 inhibition (apremilast) at the clinical and monocyte subset level. Subjects aged 18-65 with moderate-to-severe psoriasis enrolled into a 16-week clinical trial with apremilast standard dosing. Entry criteria included elevated levels of AM-endotype, defined as hyperadhesive monocyte doublets, monocyte platelet aggregates (MPAs), or intermediate monocytes > 150% of healthy control values.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
